ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Berlin, BE, DEU:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Berlin, Germany and 66 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, Germany and 73 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

Berlin, Germany and 186 other locations

of BCL6 (BCL6 LDD), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin...

Enrolling
Relapsed/Refractory Non-Hodgkin Lymphoma
Drug: Rituximab
Drug: BMS-986458

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, Germany and 21 other locations

monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have received at least tw...

Begins enrollment this month
B-cell Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Drug: AZD0486

Phase 2

AstraZeneca
AstraZeneca

Berlin, Germany and 44 other locations

Locations recently updated

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this stud...

Enrolling
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: ABBV-525

Phase 1

AbbVie
AbbVie

Berlin, Germany and 26 other locations

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma...

Active, not recruiting
Lymphoma, Non-Hodgkin
Device: Oxaliplatin
Drug: Rituximab

Phase 2, Phase 3

Universität des Saarlandes

Berlin, Germany and 76 other locations

cancer treatment and have also shown first encouraging results in Non-Hodgkin lymphomas. Based on these observations it is...

Enrolling
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Pembrolizumab
University of Ulm

Berlin, Germany and 13 other locations

in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem ...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: R-GemOx or BR plus polatuzumab vedotin
Genetic: MB-CART2019.1

Phase 2

Miltenyi Biotec
Miltenyi Biotec

Berlin, Germany and 53 other locations

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this dise...

Enrolling
Follicular Lymphoma (FL)
Drug: Lenalidomide
Drug: Epcoritamab

Phase 3

Genmab
Genmab

Berlin, Germany and 271 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems